Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label, Multi-centered, Randomized Phase 2 Study to Evaluate the Safety, Tolerability and Bioactivity of Subcutaneous ACTH GeL in PAtients With Scleritis: The ATLAS Study

Next Previous
Trial Profile

An Open Label, Multi-centered, Randomized Phase 2 Study to Evaluate the Safety, Tolerability and Bioactivity of Subcutaneous ACTH GeL in PAtients With Scleritis: The ATLAS Study

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Aug 2018

At a glance

  • Drugs Corticotropin (Primary)
  • Indications Scleritis
  • Focus Therapeutic Use
  • Acronyms ATLAS

    • Most Recent Events

    • 14 Aug 2018 Planned primary completion date changed from 30 May 2019 to 30 Sep 2019.
    • 14 Aug 2018 Planned initiation date changed from 1 Mar 2018 to 15 Sep 2018.
    • 16 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top